BGE-102 and the Inflammaging Bet: An Oral NLRP3 Inhibitor Cut hsCRP ~85% in a Phase 1 Trial

In April 2026, a small California biotech called BioAge Labs reported something that, on the surface, looks remarkable: a once-daily pill that cut a key marker of inflammation by roughly 85% in people with obesity — and was well tolerated doing it. [1]

The drug is BGE-102, an oral NLRP3 inhibitor, and the marker is hsCRP (high-sensitivity C-reactive protein), one of the most-studied readouts of chronic inflammation in the body. It's a genuinely interesting result on a target that sits near the center of how we think about aging. It's also a Phase 1 biomarker result in about two dozen people over three weeks — which means the exciting part and the "don't get ahead of yourself" part are the same sentence. Like our look at the one-time gene edit that lowers cholesterol for life, the caveats matter as much as the headline. Here's the honest version.

What BioAge actually reported

The Phase 1 trial was randomized, double-blind, and placebo-controlled. The cohorts that produced these headline numbers were people with obesity (BMI 32–42) and elevated baseline inflammation (hsCRP above 3 mg/L) — exactly the population where an anti-inflammatory drug should have room to work. Two once-daily oral doses were reported: [1]

• 60 mg for 21 days: hsCRP fell 85% by day 7, 80% by day 14, and 86% by day 21. By day 21, 87% (13 of 15) of participants on active drug had pushed hsCRP into the normal range (below 2 mg/L), and 60% (9 of 15) got it to 1 mg/L or lower.
• 120 mg for 14 days: hsCRP fell 83% by day 7 and 86% by day 14, with 93% (13 of 14) reaching below 2 mg/L.

The notable wrinkle: the lower 60 mg dose essentially matched the 120 mg dose, which suggests the effect plateaus and a smaller daily dose may do the job. [1] Reductions in IL-6 — another inflammatory signal independently tied to cardiovascular risk — moved in the same direction, and earlier healthy-volunteer data showed the drug crosses into the brain and suppresses IL-1β. [1] Across all dose levels, BioAge described BGE-102 as well tolerated. [1]

Those are strong pharmacodynamic numbers. But keep two things in mind: the cohorts are small (14–15 people on drug), the dosing is short (2–3 weeks), and hsCRP is a marker, not a health outcome. More on that below.

NLRP3, "inflammaging," and why BioAge is chasing it

NLRP3 is an inflammasome — a sensor complex inside immune cells that, when triggered, releases the inflammatory messengers IL-1β and IL-18. It's meant to fire in short bursts against infection or injury. The problem is that with age, obesity, and metabolic stress, NLRP3 starts smoldering chronically — a low-grade, body-wide inflammation researchers nickname "inflammaging." [1]

That smolder isn't cosmetic. NLRP3-driven inflammation has been implicated in cardiovascular disease, metabolic disease (including obesity itself), and neurodegeneration. [1] BioAge says its angle came from analyzing human aging cohorts, where lower NLRP3 activity tracked with greater longevity — which is why it built a brain-penetrant inhibitor and is pointing it at heart, eye, and brain diseases as a "pipeline in a pill." [1]

Why hsCRP is the number to watch — the CANTOS precedent

Here's the context that turns "a pill lowered a lab value" into "this could matter." Cardiology has known for years about residual inflammatory risk: plenty of patients keep having heart attacks even with cholesterol driven low, and the ones with stubbornly high hsCRP carry the highest residual risk. [3]

The landmark CANTOS trial (10,061 post–heart-attack patients) tested that head-on with canakinumab, an antibody against IL-1β — the exact signal NLRP3 controls. Canakinumab lowered hsCRP by 26–41% and cut major cardiovascular events (heart attack, stroke, CV death) by about 15%, with the biggest benefit in patients who reached hsCRP below 2 mg/L — and it did so without changing cholesterol at all. [2][3] It was the first hard proof that lowering inflammation, by itself, prevents cardiovascular events.

But canakinumab never became a heart drug: it's an expensive injectable, it raised fatal infections, and the benefit, while real, was modest. [2] That left a gap the whole field is racing to fill — a safe, cheap, oral way to capture the CANTOS benefit. Against that backdrop, a pill that drops hsCRP ~85% is eye-catching. The honest asterisk: CANTOS proved the outcome (fewer events) over years; BGE-102 has so far proven the biomarker (lower hsCRP) over weeks. Those are not the same thing — the history of medicine is full of biomarkers that moved beautifully without improving outcomes. BioAge's planned Phase 2 cardiovascular-risk trial is where that question finally gets tested. [1]

"Best-in-class" — in a crowded race

BioAge calls BGE-102 a "potential best-in-class" NLRP3 inhibitor. That's fair marketing, but it's worth knowing it's not running alone. Oral, brain-penetrant NLRP3 inhibitors are one of the hotter races in inflammation: [4][5][6]

• NodThera reported its oral, brain-penetrant inhibitor (NT-0796) in a Phase 1b/2a cardiovascular-risk study in inflamed, obese subjects — essentially the same playbook. [4]
• Ventus Therapeutics has VENT-02, another oral brain-penetrant NLRP3 inhibitor through Phase 1. [5]
• Olatec's dapansutrile is an oral NLRP3 inhibitor already in Phase 2 across gout, Parkinson's and more. [6]
• Larger players (including Novo Nordisk) have NLRP3 programs too. [5]

So the real question isn't whether NLRP3 can be drugged orally — several companies are showing it can — but which molecule wins on the combination of potency, safety, brain penetration, and, ultimately, outcomes. BGE-102's depth of hsCRP reduction and low effective dose are points in its favor; the field is far from settled.

The BioAge backstory matters here

This result also lands as a comeback for BioAge. Its previous lead program, azelaprag (an oral apelin-receptor agonist meant to pair with GLP-1 drugs like tirzepatide for obesity), was halted in December 2024 when its Phase 2 STRIDES trial turned up liver-enzyme elevations in a subset of participants, and the stock fell hard. [7] BioAge pivoted to its NLRP3 program, nominated BGE-102 as the new lead, and these Phase 1 data are the first big readout of that bet. [7][8] Pivots are normal in biotech — but it's useful context for why the framing is so bullish, and a reminder that tolerability over longer dosing is the thing to watch, given the company's recent history.

What this does — and doesn't — mean

To keep it straight:

• It does show that an oral, once-daily pill can profoundly and (so far) safely lower inflammatory markers in the right population — strong proof of pharmacology and target engagement.
• It doesn't show the drug prevents heart attacks, improves diabetic eye disease, protects the brain, extends healthspan, or treats obesity. Those are hypotheses the planned Phase 2 (cardiovascular risk) and Phase 1b/2a (diabetic macular edema) trials — both slated to start in 2026 — are designed to begin testing. [1]
• The n is small and the dosing short, "best-in-class" is company language, and the long-term safety of chronically dialing down a core immune sensor (think infection risk — the CANTOS lesson) is unproven for any oral NLRP3 inhibitor.

In short: a real, encouraging data point on one of the most important targets in aging biology — early, not destiny.

Where peptides fit (and where they don't)

If you follow research peptides, the inflammation angle will sound familiar. Several of the most-studied peptides are explored precisely for calming inflammation — the α-MSH fragment KPV, BPC-157, Thymosin Alpha-1, and the mitochondrial peptide SS-31. It's tempting to file BGE-102 alongside them.

Resist that. The honest distinction is evidence and precision: BGE-102 is a clinical-stage drug with a defined molecular target (NLRP3) and randomized, placebo-controlled human Phase 1 data. The anti-inflammatory peptides are research compounds whose human evidence is far earlier and thinner, often resting on animal models and self-report (we cover that honestly in our BPC-157 human-evidence reality check). They share a theme — chronic inflammation is a worthy target — but they are not the same tier of proof. BGE-102 is also a small molecule, not a peptide, and, to be explicit, an investigational drug you cannot buy.

Bottom line

BGE-102's Phase 1 is one of the more striking biomarker readouts in the inflammaging space: a once-daily oral pill driving ~85% hsCRP reductions, at a low dose, with clean tolerability so far. [1] Riding on it is the decades-old, CANTOS-validated idea that taming inflammation can protect the cardiovascular system — now potentially in a form patients would actually take. [2] Whether BGE-102 specifically converts that promise into outcomes — and beats a crowded field of oral NLRP3 rivals — is a 2026–2027 story. For now: real signal, honest uncertainty.

This article is research and news commentary, not medical advice. BGE-102 is an investigational drug and is not available for purchase.

Sources

1. BioAge Labs — "BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor…" (GlobeNewswire, Apr 21, 2026).
2. Ridker PM, et al. — "Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease" (CANTOS), New England Journal of Medicine, 2017.
3. American College of Cardiology — CANTOS trial summary.
4. NodThera — oral brain-penetrant NLRP3 inhibitor (NT-0796) program.
5. DelveInsight — NLRP3 inhibitor clinical-development landscape, 2025 (Ventus, Olatec, Novo Nordisk and others).
6. Olatec Therapeutics — dapansutrile Phase 2 program.
7. BioPharma Dive — BioAge halts azelaprag/tirzepatide STRIDES trial (Dec 2024).
8. BioAge Labs — company updates on APJ, NLRP3, and platform programs (Jan 2025).